
    
      This is a 62 week (including screening and follow-up), multicenter, randomized, double blind,
      placebo-controlled, parallel group study in male and female patients with a histological
      diagnosis of NASH. The study includes a screening period, double blind treatment period, and
      post-treatment follow up
    
  